NO20054556L - Amylinaggregeringsinhibitorer og anvendelse derav - Google Patents

Amylinaggregeringsinhibitorer og anvendelse derav

Info

Publication number
NO20054556L
NO20054556L NO20054556A NO20054556A NO20054556L NO 20054556 L NO20054556 L NO 20054556L NO 20054556 A NO20054556 A NO 20054556A NO 20054556 A NO20054556 A NO 20054556A NO 20054556 L NO20054556 L NO 20054556L
Authority
NO
Norway
Prior art keywords
type
aggregation inhibitors
diabetes
peptides
derivatives
Prior art date
Application number
NO20054556A
Other languages
English (en)
Inventor
Claudio Soto-Jara
Youcef Fezoui
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of NO20054556L publication Critical patent/NO20054556L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

2005-10-04 SAMMENDRAG Det er beskrevet korte pept ider og derivater eller analoger derav til behandling eller forhindring av IAAP-relaterte lidelser, særlig amyloide avsetninger assosiert med type I eller type II diabetes. Disse peptider og/eller deres derivater er blitt konstruert for å inhibere dannelsen av amylinfibriller som er involvert i patogenesen til diabetes type II så vel som å oppløse de fibrillære avsetninger allerede dannet.
NO20054556A 2003-03-18 2005-10-04 Amylinaggregeringsinhibitorer og anvendelse derav NO20054556L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03100683 2003-03-18
PCT/EP2004/050320 WO2004083243A1 (en) 2003-03-18 2004-03-17 Amylin aggregation inhibitors and use thereof.

Publications (1)

Publication Number Publication Date
NO20054556L true NO20054556L (no) 2005-10-04

Family

ID=33016961

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054556A NO20054556L (no) 2003-03-18 2005-10-04 Amylinaggregeringsinhibitorer og anvendelse derav

Country Status (7)

Country Link
US (1) US20070155955A1 (no)
EP (1) EP1603944A1 (no)
JP (1) JP2007527365A (no)
AU (1) AU2004222110A1 (no)
CA (1) CA2516726A1 (no)
NO (1) NO20054556L (no)
WO (1) WO2004083243A1 (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU20130027A7 (es) 2013-02-28 2014-10-30 Ct De Neurociencias De Cuba Chaperoninas químicas como nuevos moduladores moleculares de la beta agregación proteica presente en las enfermedades conformacionales
EP3927725A4 (en) * 2019-02-22 2023-06-14 Loyola Marymount University AMYLOID PEPTIDE VARIANTS
CN110240632B (zh) * 2019-04-18 2022-11-25 华东理工大学 一种Amylin亲和多肽及其应用
WO2024076285A1 (en) * 2022-10-05 2024-04-11 Ivarsson Ylva Peptide targeting sars-cov-2 nsp9

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2130463C1 (ru) * 1991-11-19 1999-05-20 Амилин Фармасьютикалз, Инк. Аналог-агонист амилина, его фармацевтически приемлемые соли, композиция, проявляющая свойства агониста амилина
US5948763A (en) * 1995-06-07 1999-09-07 New York University Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
DE19725619A1 (de) * 1997-06-17 1998-12-24 Fraunhofer Ges Forschung Peptide als Agonisten und/oder Inhibitoren der Amyloidbildung und Zytotoxizität sowie der Verwendung bei Alzheimer'schen Krankheit, beim Typ II Diabetes mellitus und bei spongiformen Encephalopathien
CA2422911A1 (en) * 2000-09-19 2002-03-28 Paul Fraser New inhibitors of iapp fibril formation and uses thereof

Also Published As

Publication number Publication date
JP2007527365A (ja) 2007-09-27
US20070155955A1 (en) 2007-07-05
WO2004083243A1 (en) 2004-09-30
CA2516726A1 (en) 2004-09-30
EP1603944A1 (en) 2005-12-14
WO2004083243A8 (en) 2005-03-17
AU2004222110A1 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
NO20080745L (no) Nye peptider for anvendelse i behandling av fedme
DE602008005155D1 (de) Glp-1-fc fusionsprotein-formulierung
CY1111212T1 (el) Θειικες ενωσεις ως αναστολεις της πρωτεασης σερινης ns3 του ιου της ηπατιτιδας γ
NO20081354L (no) Dobbelt variabelt domeneimmunoglobin samt fremgangsmater derav
DE602005012306D1 (de) Cycloalkyl-lactam-derivate als inhibitoren von 11-beta-hydroxysteroiddehydrogenase 1
DK1735296T3 (da) Materialer og fremgangsmåder til behandling af koagulationslidelser
NO20064347L (no) Substituerte 1,2,3,4-tetrahydroisokinolinderivater
DK1891105T3 (da) Hidtil ukendte forbindelser og deres påvirkninger på spiseadfærd
JP2019506159A5 (no)
EA200702392A1 (ru) Пептид, композиция на его основе, стент с его использованием для лечения патологий, связанных воспалительными процессами, и способ изготовления указанного стента
MY165889A (en) Compositions and methods of using proislet peptides and analogs thereof
CY1111225T1 (el) Νεα πεπτιδια ως αναστολεις πρωτεασης νs3-σερινης ιου ηπατiτιδας c
NO20055211L (no) Anti-fungale forbindelser og fremgangsmater for anvendelse
NO20063026L (no) Antistoffer
NO20061479L (no) Anvendelse av modifiserte cyklosporiner for behandling av HCV-forstyrrelser
NO20052595L (no) Sammensetninger anvendelige som inhibitorer av ROCK- og andre proteinkinaser.
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
ES2617920T3 (es) Métodos para el tratamiento de la coagulación intravascular diseminada mediante la inhibición de la activación del complemento dependiente de MASP-2
DE602006010834D1 (de) Neue thiophensulfoximine zur behandlung von komplementvermittelten krankheiten und leiden
NO20064325L (no) Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes
NO20083104L (no) Fast preparat
ATE457736T1 (de) Zusammensetzung aus einem pulmonalen surfactant und einem von tnf stammenden peptid
EA200100937A1 (ru) Способы и композиции, использующие (-)-норцисаприд в комбинации с ингибиторами протонных насосов или антагонистами h2-рецепторов
EA200970981A1 (ru) Пептидная смесь в качестве стабилизатора вина
DE602006012115D1 (de) Behandlung von amyotrophischer lateralsklerose mit pyrimethamin und analoga

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS

FC2A Withdrawal, rejection or dismissal of laid open patent application